Immunome, Inc. (IMNM)
Free
No email, no account, no signup.
Pulling latest news for Immunome, Inc.…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NASDAQ
Type
Biotech
Sector
Targeted oncology and antibody therapeutics
Market Cap
$2.6B
Market sentiment
Sentiment has improved on the NDA submission and ASCO oral selection (stronger external validation), partially offset by insider selling and ongoing binary regulatory risk.
Why NEUTRAL ?
The NDA submission and upcoming ASCO oral presentation are material catalysts that can re-rate the story, but outcomes remain binary (FDA acceptance/timeline, label/requirements). A 'review' stance is warranted rather than automatically adding/reducing ahead of more clarity.
- Maintain a core position if already owned, but avoid aggressive adds ahead of FDA acceptance/ASCO; consider scaling exposure around catalysts based on risk budget.
We're already tracking Immunome, Inc. — here are the latest events we've registered
Recent News
- Since May 8, 2026, Immunome released its Q1 2026 results (May 11), announced that Phase 3 RINGSIDE data (varegacestat in desmoid tumors) was selected for an oral presentation at ASCO 2026, and that it has formally submitted an NDA to the FDA for varegacestat. Shares moved modestly higher on earnings with elevated volume, and focus is now on FDA acceptance/review and the ASCO readout/presentation.
Want to know how this news affects Immunome, Inc.? Order the analysis.
Order analysis – $4.99
Catalysts
2 Jun 2026 — ASCO 2026: Oral presentation of Phase 3 RINGSIDE
Order analysis – $4.99
Save hours of research. $4.99.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
What you get
A complete express analysis — not just a signal. Delivered as a webpage in your account.
- Signal: BUY / HOLD / SELL — with clear reasoning
- Sentiment score 1–10 based on news, reports, and market data
- Risk score 1–10 (dilution, jurisdiction, execution)
- Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
- Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
- Upcoming catalysts with dates
- Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Immunome, Inc. will be delivered in the same format.
Not satisfied? Get your money back within 7 days — no questions asked.
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.